Rani Therapeutics Holdings, Inc. Logo

Rani Therapeutics Holdings, Inc.

Develops a capsule to convert injectable biologics into oral pills for chronic diseases.

RANI | US

Overview

Corporate Details

ISIN(s):
US7530181004
LEI:
Country:
United States of America
Address:
2051 RINGWOOD AVENUE, 95131 SAN JOSE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing orally administered biologics. The company has created the RaniPill® capsule, a proprietary and disruptive platform technology designed to convert injectable drugs, such as peptides, proteins, and antibodies, into oral pills. This technology aims to replace painful injections for patients with chronic diseases, potentially improving adherence and quality of life across a wide range of therapeutic areas. Rani's core business revolves around advancing its pipeline of oral biologic candidates through clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Rani Therapeutics Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Rani Therapeutics Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Rani Therapeutics Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Monopar Therapeutics Logo
Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.
United States of America
MNPR
Monte Rosa Therapeutics, Inc. Logo
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
United States of America
GLUE
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea
322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan
4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan
4885
MUSTANG BIO, INC. Logo
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
United States of America
MBIO
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea
017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America
NBTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.